文献速递骨质疏松与钙磷/甲状旁腺

Eneboparatide(一种新型PTH1受体激动剂)治疗甲状旁腺功能减退症的开放标签2期研究

An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

这项开放标签2期研究纳入28例慢性甲状旁腺功能减退症患者,分两个连续队列接受每日皮下注射Eneboparatide 3个月(C1起始20 µg/天,C2起始10 µg/天,可分别滴定至60 µg或80 µg)。3个月后≥88%患者脱离常规治疗,平均白蛋白校正血钙维持在目标范围7.8-9 mg/dL,24小时尿钙快速持续降低,骨转换标志物轻度升高而骨密度不变,无严重不良事件。

要点

  • Eneboparatide治疗3个月后≥88%患者脱离常规治疗,平均白蛋白校正血钙维持于7.8-9 mg/dL目标范围。
  • Eneboparatide使平均24小时尿钙快速持续降低,高钙尿症患者亦如此。
  • 骨转换标志物轻度升高而骨密度不变,无严重不良事件。

核心结论

  • Eneboparatide可使甲状旁腺功能减退症患者脱离常规治疗,血钙维持于目标范围,同时使尿钙排泄正常化并产生平衡的骨转换恢复。

研究设计与样本

  • 开放标签2期研究,纳入28例甲状旁腺功能减退症患者(21例女性,7例男性),平均年龄58岁(范围28-72岁),分两个连续队列(C1 n=12,C2 n=16)。
  • 经过优化期后,每日皮下注射Eneboparatide 3个月,C1起始剂量20 µg/天,C2起始剂量10 µg/天。
  • 常规治疗逐步撤除,Eneboparatide可分别滴定至C1最高60 µg、C2最高80 µg。

主要发现

  • 3个月后≥88%患者脱离常规治疗,平均白蛋白校正血钙维持于目标范围7.8-9 mg/dL。
  • Eneboparatide使平均24小时尿钙快速持续降低,高钙尿症患者亦如此。
  • 骨转换标志物(I型胶原羧基端交联肽和1型前胶原氨基端前肽)轻度升高,骨密度保持不变,符合生理性骨转换逐步恢复。
  • Eneboparatide耐受良好,无严重不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Hypoparathyroidism is a rare disorder characterized by a deficiency in PTH resulting in hypocalcemia, hyperphosphatemia, and hypercalciuria. Eneboparatide is an investigational peptide agonist of the PTH1 receptor for the treatment of chronic hypoparathyroidism (HP). OBJECTIVE: To evaluate the efficacy, safety, and tolerability of eneboparatide in HP patients. DESIGN: Open-label, phase 2 study. PARTICIPANTS: Twenty-eight patients (21 women, 7 men), mean age (range): 58 years (28-72), with HP were enrolled into 2 consecutive cohorts (C1, n = 12 and C2, n = 16). INTERVENTION: Following an optimization period, daily subcutaneous injections of eneboparatide were administered for 3 months at a 20 µg/day (C1) or 10 µg/day (C2) starting dose. Conventional therapy was progressively removed, and eneboparatide could be titrated up to 60 µg (C1) or 80 µg (C2). MAIN OUTCOMES: Proportion of patients achieving independence from conventional therapy, albumin-adjusted serum calcium (ADsCa), 24-h urine calcium (uCa), serum bone turnover markers (serum carboxy-terminal telopeptide of type I collagen and procollagen 1 intact N-terminal propeptide), bone mineral density (BMD), and adverse events (AEs). RESULTS: After 3 months, ≥ 88% of patients achieved independence from conventional therapy while mean ADsCa was maintained within target range (7.8-9 mg/dL). Eneboparatide induced a rapid and sustained reduction of mean 24-hour uCa, even among patients with hypercalciuria. Bone turnover markers slightly increased, and BMD remained unchanged, consistent with progressive resumption of physiologic bone turnover. Eneboparatide was well tolerated with no serious AEs. CONCLUSION: Eneboparatide allowed independence from conventional therapy and maintenance of serum calcium within a target range while normalizing uCa excretion and producing a balanced resumption of bone turnover.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Takacs I, Mezosi E, Soto A, et al. An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism. J Clin Endocrinol Metab. 2024. PMID: 38449442. doi:10.1210/clinem/dgae121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。